Reaching Those in Need
Preparing for Pretomanid
TB Alliance’s “AAA mandate,” has committed the organization to ensuring that all new treatments will be adopted, available and affordable to those with TB. With regulatory submissions planned or underway, TB Alliance has been working to enable quick and widespread access to pretomanid and the BPaL regimen at affordable prices pending regulatory approvals. Major achievements to date include building a foundation for commercialization partnerships for pretomanid as part of the BPaL and BPaMZ regimens, as well as engaging with additional generic manufacturers to foster competition and ensure sustainability and affordability of new treatments.
Partnerships to End Childhood TB
Each year, one million children get sick with TB and about 210,000 needlessly die. That's nearly 600 preventable child deaths each day.
TB Alliance and partners have worked to help end the neglect of children with TB. Upon developing TB medicines in correct doses and appropriate forms and tastes for children, we sought partnerships with manufacturers who could help drive widespread uptake of these improved therapies. Macleods Pharmaceuticals was a key partner in our efforts, spearheading critical formulation and development work that helped these new medicines reach children in need as quickly as possible. With the assistance of a diverse network of partners, more than 800,000 courses of improved TB treatment for children have been ordered, benefitting children and families around the world.